Cargando…

Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma

SIMPLE SUMMARY: Intrahepatic cholangiocarcinoma (ICC) is a primary liver cancer that currently has limited treatment options. As a result, patients with this disease generally have a poor prognosis. Previous studies have demonstrated that mutations in KRAS and loss of BRCA-1-associated protein 1 (BA...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcus, Rebecca, Ferri-Borgogno, Sammy, Hosein, Abdel, Foo, Wai Chin, Ghosh, Bidyut, Zhao, Jun, Rajapakshe, Kimal, Brugarolas, James, Maitra, Anirban, Gupta, Sonal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616431/
https://www.ncbi.nlm.nih.gov/pubmed/34830866
http://dx.doi.org/10.3390/cancers13225709
_version_ 1784604346707607552
author Marcus, Rebecca
Ferri-Borgogno, Sammy
Hosein, Abdel
Foo, Wai Chin
Ghosh, Bidyut
Zhao, Jun
Rajapakshe, Kimal
Brugarolas, James
Maitra, Anirban
Gupta, Sonal
author_facet Marcus, Rebecca
Ferri-Borgogno, Sammy
Hosein, Abdel
Foo, Wai Chin
Ghosh, Bidyut
Zhao, Jun
Rajapakshe, Kimal
Brugarolas, James
Maitra, Anirban
Gupta, Sonal
author_sort Marcus, Rebecca
collection PubMed
description SIMPLE SUMMARY: Intrahepatic cholangiocarcinoma (ICC) is a primary liver cancer that currently has limited treatment options. As a result, patients with this disease generally have a poor prognosis. Previous studies have demonstrated that mutations in KRAS and loss of BRCA-1-associated protein 1 (BAP1) are frequently found in ICC. We developed a mouse model for ICC that incorporates KRAS and BAP1 mutations in a liver-dependent fashion to aid in the improvement of our understanding of this devastating disease. Our findings suggest that complete loss of BAP1 function combined with mutant KRAS appears to be a requirement for inducing ICC formation within the liver. ABSTRACT: Intrahepatic cholangiocarcinoma (ICC) is a primary biliary malignancy that harbors a dismal prognosis. Oncogenic mutations of KRAS and loss-of-function mutations of BRCA1-associated protein 1 (BAP1) have been identified as recurrent somatic alterations in ICC. However, an autochthonous genetically engineered mouse model of ICC that genocopies the co-occurrence of these mutations has never been developed. By crossing Albumin-Cre mice bearing conditional alleles of mutant Kras and/or floxed Bap1, Cre-mediated recombination within the liver was induced. Mice with hepatic expression of mutant Kras(G12D) alone (KA), bi-allelic loss of hepatic Bap1 (B(homo)A), and heterozygous loss of Bap1 in conjunction with mutant Kras(G12D) expression (B(het)KA) developed primary hepatocellular carcinoma (HCC), but no discernible ICC. In contrast, mice with homozygous loss of Bap1 in conjunction with mutant Kras(G12D) expression (B(homo)KA) developed discrete foci of HCC and ICC. Further, the median survival of B(homo)KA mice was significantly shorter at 24 weeks when compared to the median survival of ≥40 weeks in B(het)KA mice and approximately 50 weeks in B(homo)A and KA mice (p < 0.001). Microarray analysis performed on liver tissue from KA and B(homo)KA mice identified differentially expressed genes in the setting of BAP1 loss and suggests that deregulation of ferroptosis might be one mechanism by which loss of BAP1 cooperates with oncogenic Ras in hepato-biliary carcinogenesis. Our autochthonous model provides an in vivo platform to further study this lethal class of neoplasm.
format Online
Article
Text
id pubmed-8616431
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86164312021-11-26 Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma Marcus, Rebecca Ferri-Borgogno, Sammy Hosein, Abdel Foo, Wai Chin Ghosh, Bidyut Zhao, Jun Rajapakshe, Kimal Brugarolas, James Maitra, Anirban Gupta, Sonal Cancers (Basel) Article SIMPLE SUMMARY: Intrahepatic cholangiocarcinoma (ICC) is a primary liver cancer that currently has limited treatment options. As a result, patients with this disease generally have a poor prognosis. Previous studies have demonstrated that mutations in KRAS and loss of BRCA-1-associated protein 1 (BAP1) are frequently found in ICC. We developed a mouse model for ICC that incorporates KRAS and BAP1 mutations in a liver-dependent fashion to aid in the improvement of our understanding of this devastating disease. Our findings suggest that complete loss of BAP1 function combined with mutant KRAS appears to be a requirement for inducing ICC formation within the liver. ABSTRACT: Intrahepatic cholangiocarcinoma (ICC) is a primary biliary malignancy that harbors a dismal prognosis. Oncogenic mutations of KRAS and loss-of-function mutations of BRCA1-associated protein 1 (BAP1) have been identified as recurrent somatic alterations in ICC. However, an autochthonous genetically engineered mouse model of ICC that genocopies the co-occurrence of these mutations has never been developed. By crossing Albumin-Cre mice bearing conditional alleles of mutant Kras and/or floxed Bap1, Cre-mediated recombination within the liver was induced. Mice with hepatic expression of mutant Kras(G12D) alone (KA), bi-allelic loss of hepatic Bap1 (B(homo)A), and heterozygous loss of Bap1 in conjunction with mutant Kras(G12D) expression (B(het)KA) developed primary hepatocellular carcinoma (HCC), but no discernible ICC. In contrast, mice with homozygous loss of Bap1 in conjunction with mutant Kras(G12D) expression (B(homo)KA) developed discrete foci of HCC and ICC. Further, the median survival of B(homo)KA mice was significantly shorter at 24 weeks when compared to the median survival of ≥40 weeks in B(het)KA mice and approximately 50 weeks in B(homo)A and KA mice (p < 0.001). Microarray analysis performed on liver tissue from KA and B(homo)KA mice identified differentially expressed genes in the setting of BAP1 loss and suggests that deregulation of ferroptosis might be one mechanism by which loss of BAP1 cooperates with oncogenic Ras in hepato-biliary carcinogenesis. Our autochthonous model provides an in vivo platform to further study this lethal class of neoplasm. MDPI 2021-11-15 /pmc/articles/PMC8616431/ /pubmed/34830866 http://dx.doi.org/10.3390/cancers13225709 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Marcus, Rebecca
Ferri-Borgogno, Sammy
Hosein, Abdel
Foo, Wai Chin
Ghosh, Bidyut
Zhao, Jun
Rajapakshe, Kimal
Brugarolas, James
Maitra, Anirban
Gupta, Sonal
Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
title Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
title_full Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
title_fullStr Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
title_full_unstemmed Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
title_short Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
title_sort oncogenic kras requires complete loss of bap1 function for development of murine intrahepatic cholangiocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616431/
https://www.ncbi.nlm.nih.gov/pubmed/34830866
http://dx.doi.org/10.3390/cancers13225709
work_keys_str_mv AT marcusrebecca oncogenickrasrequirescompletelossofbap1functionfordevelopmentofmurineintrahepaticcholangiocarcinoma
AT ferriborgognosammy oncogenickrasrequirescompletelossofbap1functionfordevelopmentofmurineintrahepaticcholangiocarcinoma
AT hoseinabdel oncogenickrasrequirescompletelossofbap1functionfordevelopmentofmurineintrahepaticcholangiocarcinoma
AT foowaichin oncogenickrasrequirescompletelossofbap1functionfordevelopmentofmurineintrahepaticcholangiocarcinoma
AT ghoshbidyut oncogenickrasrequirescompletelossofbap1functionfordevelopmentofmurineintrahepaticcholangiocarcinoma
AT zhaojun oncogenickrasrequirescompletelossofbap1functionfordevelopmentofmurineintrahepaticcholangiocarcinoma
AT rajapakshekimal oncogenickrasrequirescompletelossofbap1functionfordevelopmentofmurineintrahepaticcholangiocarcinoma
AT brugarolasjames oncogenickrasrequirescompletelossofbap1functionfordevelopmentofmurineintrahepaticcholangiocarcinoma
AT maitraanirban oncogenickrasrequirescompletelossofbap1functionfordevelopmentofmurineintrahepaticcholangiocarcinoma
AT guptasonal oncogenickrasrequirescompletelossofbap1functionfordevelopmentofmurineintrahepaticcholangiocarcinoma